XETRA - Delayed Quote EUR

Apontis Pharma AG (APPH.DE)

12.05
0.00
(0.00%)
At close: June 10 at 5:36:22 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Bruno Eugen Wohlschlegel CEO & Chairman of Management Board 430k -- 1968
Mr. Thomas Milz Chief Product Officer & Deputy Chairman of Management Board 349k -- --
Mr. Thomas Zimmermann CFO & Member of Management Board 215k -- --

Apontis Pharma AG

Alfred-Nobel-Str. 10
Monheim am Rhein, 40789
Germany
49 2173 8955 4949 https://apontis-pharma.de
Sector: 
Healthcare
Full Time Employees: 
137

Description

Apontis Pharma AG engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prophylaxis, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. As of November 21, 2024, Apontis Pharma AG operates as a subsidiary of Zentiva AG.

Corporate Governance

Apontis Pharma AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

March 28, 2025 at 10:59 AM UTC - March 31, 2025 at 12:00 PM UTC

Apontis Pharma AG Earnings Date

Recent Events

Related Tickers